DRD2 GWAS signals drove enrichment for all schizophrenia treatments; a post hoc analysis excluding therapeutics that were only enriched due to DRD2 GWAS signals still revealed significant enrichment for SCZ treatments (OR = 19.49; p = 2.47e−4). The gene discussed is DRD2; the disease is schizophrenia.